The University of Miami Health System is starting a clinical trial to further evaluate the safety and efficacy of an investigational cell therapy for the treatment of chronic motor deficit following an ischemic stroke. The Phase 2b study will be led by Dileep Yavagal, M.D., director of interventional neurology and a member of the Interdisciplinary Stem Cell Institute at the University of Miami, which is conducting a number of FDA-approved clinical trials in stem cell therapy. Jonathan Jagid, M.D., associate professor of neurological surgery, is the surgical principal investigator of the trial.
“The debilitating effects of an ischemic stroke cause impaired motor skills and decrease a patient’s quality of life significantly,” said Yavagal, who is associate professor of neurology and neurological surgery at the University of Miami Miller School of Medicine. “Our goal at the Interdisciplinary Stem Cell Institute is to find viable treatment options to improve serious disabilities from strokes that will one day be used in clinical application. The ACTIsSIMA trial (Allogenic Cell Therapy for Ischemic Stroke to Improve Motor Abilities) will help determine whether this investigational cell therapy is a safe and effective treatment option for chronic stroke.”
Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that p300, a protein that increases gene expression by attaching acetyl molecules to DNA, may stop myelodysplastic syndrome (MDS) from developing into acute myeloid leukemia (AML). The study was published in the journal Leukemia.
Following early-stage development of a vaccine to protect against the Zika virus, a group of researchers at the University of Miami Miller School of Medicine has published its initial findings. Now, with new funding, they are moving forward with non-human primate testing and, eventually, phase I human trials.
A Florida mother is thanking University of Miami Health System doctors after they removed two benign brain tumors strangling her optic nerves and restored her sight – all while she was six months pregnant.
Researchers at Bascom Palmer Eye Institute, part of the University of Miami Miller School of Medicine, have identified a new molecule that induces the formation of abnormal blood vessels in the eyes of diabetic mice. The study suggests that inhibiting this molecule may prevent similarly aberrant blood vessels from damaging the vision of not only diabetics, but also premature infants.
Screams of joy extended far beyond the Schoninger Research Quadrangle on Friday as members of the Miller School of Medicine Class of 2017 joined medical students all over the country for Match Day, when they learn where they will spend the next several years of their training.